Trial Profile

Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavacamten (Primary)
Indications Dilated cardiomyopathy; Hypertrophic cardiomyopathy
Focus Adverse reactions
Sponsors MyoKardia

Most Recent Events

16 Nov 2016 Results from NCT02329184 and NCT02356289 studies, presented at the 89th Annual Scientific Sessions of the American Heart Association.
11 Jul 2016 Results from this trial have been submitted for presentation at The American Heart Association's Scientific Sessions 2016, according to a MyoKardia media release.
11 Jul 2016 Results published in a MyoKardia media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com